Short answer
CapsoVision, Inc (CV) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA clearance received September 25, 2026 for AI Highlights™, an AI-assisted reading feature.
CapsoVision, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA clearance received September 25, 2026 for AI Highlights™, an AI-assisted reading feature
- Feature integrates with CapsoCam Plus®, potentially strengthening product differentiation
- Regulatory clearance enables U.S. commercialization subject to applicable launch plans
- Press release filed as Exhibit 99.1 with additional product and market details
Item EX-99.1 · Exhibit EX-99.1
- FDA clearance received September 25, 2026 for AI Highlights, expanding CapsoVision’s U.S. commercial product offering
- Tool targets suspected small bowel bleeding studies in adults and children over age 2
- AI flags suspected abnormal lesions to prioritize physician review, potentially reducing interpretation time
- Integration with CapsoView and CapsoCloud strengthens platform ecosystem and supports remote review workflows
- Commercial impact depends on physician adoption, reimbursement, and demonstrated efficiency benefits; tool does not replace gastroenterologist diagnosis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CapsoVision, Inc 8-K filings
Get the next CV 8-K as it lands
Follow CV for push alerts, or ask the research agent what this filing means.